Introduction: Gestational Diabetes Mellitus (GDM) has been associated with complications both in the neonate and in the mother; including increased risk of Type 2 Diabetes Mellitus (DM2), obesity, and cardiovascular disease. Fibroblast growth factor 21 (FGF21) is a key regulator of glucose and lipid metabolism. Recently, the relationship between FGF21 and metabolic component diseases such as diabetes mellitus and obesity has been demonstrated. In addition, FGF21 mRNA and protein levels, as well as soluble levels of this molecule, have been reported to be increased in patients with GDM compared to normoglycemic pregnant women.
Objective: To associate FGF21 serum levels with metabolic profile of patients with GDM.
Material and methods: Twenty patients with GDM and fifteen clinically healthy pregnant women were included; serum FGF21 levels were determined by ELISA, and glucose, triglycerides, total cholesterol, HDL, LDL and VLDL values were measured.
Results: Our results shown that serum levels of FGF21 are significantly higher in the group of patients with GDM compared to the control group (313.72±84.58 vs 116.46±31.41 pg/mL, P=0.013). The values of triglycerides, cholesterol and VLDL showed a similar behavior between groups; while HDL levels were higher in the control group. Serum FGF21 levels positively correlated with triglyceride values (r=0.344, P·0.05) and postprandial glucose (r=0.356, P·0.05). There was no correlation between total cholesterol, HDL, LDL and VLDL levels and FGF21 levels in our study group.
Conclusion: The FGF21 molecule may play an important role in the GDM pathophysiology, since it alters the metabolic profile, both glycemic and lipid, of these patients.
20 - 23 May 2017
European Society of Endocrinology